UB Paderborn / Katalog / Suche / in CDI

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14276-e14276

2019

Link zum Volltext

Verfügbarkeit prüfen

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20573-e20573

2018

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20083-e20083

2019

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20689-e20689

2019

Link zum Volltext

Verfügbarkeit prüfen

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14711-e14711

2019

Link zum Volltext

Verfügbarkeit prüfen

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Journal of clinical oncology, 2022-09, Vol.40 (27), p.JCO2102641-3171

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16097-e16097

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16290-e16290

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2576-2576

2023

Link zum Volltext

Verfügbarkeit prüfen

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

Journal of clinical oncology, 2023-01, Vol.41 (3), p.651-663

2023

Link zum Volltext

Verfügbarkeit prüfen

The correlation between immune status of patients and their prognosis in non-small cell lung cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e23192-e23192

2017

Link zum Volltext

Verfügbarkeit prüfen

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR -mutant non–small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9116-9116

2022

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e18502-e18502

2019

Link zum Volltext

Verfügbarkeit prüfen

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA1013-LBA1013

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2536-2536

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3547-3547

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9081-9081

2023

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9101-9101

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.3582-3582

2022

Link zum Volltext

Verfügbarkeit prüfen

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9027-9027

2022

Link zum Volltext

Verfügbarkeit prüfen

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9096-9096

2022

Link zum Volltext

Verfügbarkeit prüfen

Cost-effectiveness analysis of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20556-e20556

2019

Link zum Volltext

Verfügbarkeit prüfen

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2570-2570

2023

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( EGFR m + ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9001-9001

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1087-1087

2021

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Comprehensive analysis of immune indicators provides prognostic markers for early stage non-small cell lung cancer

FLI1 circular RNA as biomarkers for tracking disease progression and as potential therapeutic targets in small cell lung cancer

Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China

Cost-effectiveness of PD-L1 testing and tumor mutational burden testing of immune checkpoint inhibitors for non-small cell lung cancer

Effect of MALAT1 in the crosstalk between nucleus and mitochondria on mitochondrial reprogramming in hepatocellular carcinoma cells

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study

A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of αvβ3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma

Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study

Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

The correlation between immune status of patients and their prognosis in non-small cell lung cancer

Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR -mutant non–small cell lung cancer (NSCLC)

Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation

TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)

Phase Ib/IIa safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced solid tumors

A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer

Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 study

Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study

A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer

A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non–small cell lung cancer (NSCLC)

Aumolertinib activity in patients with CNS metastases and EGFR-mutated NSCLC treated in the randomized double-blind phase III trial (AENEAS)

Cost-effectiveness analysis of icotinib versus whole-brain irradiation with or without chemotherapy in EGFR-mutant NSCLC patients with brain metastases

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker

Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( EGFR m + ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation

Aktive Filter

Suchergebnisse filtern